Abstract: Provided herein are methods for refolding proteins that are denatured. Exemplary methods comprise solubilizing the denatured protein with a denaturing agent, e.g., a chaotropic agent, and renaturing the protein using a buffer exchanging system, e.g., tangential flow filtration (TFF).
Type:
Grant
Filed:
December 5, 2018
Date of Patent:
July 6, 2021
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Benjamin C. Blum, Christopher Hollander
Abstract: An arginine-rich polypeptide composition includes an arginine-rich polypeptide and a pharmaceutically acceptable carrier. Generally, the arginine-rich polypeptide has at least nine arginine residues that represent at least 10% of the amino acid residues in the polypeptide. The arginine-rich polypeptide may be used in a method of inhibiting a human papilloma virus (HPV) from binding to a cell, a method of inhibiting intracellular processing of human papilloma virus (HPV) by a cell, or a method of treating a subject having, or at risk of having, a human papilloma virus (HPV) infection.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
June 29, 2021
Assignee:
UNM Rainforest Innovations
Inventors:
Zurab Surviladze, Michelle A. Ozbun, Andrew Cowan
Abstract: An active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof, which belongs to the technical field of preparing drugs for treating retinal neurodegenerative diseases, are described. The amino acid sequence of the active peptide for enhancing the phagocytic functions of retinal pigment epithelium described in the disclosure was as shown in SEQ ID NO.1. The active peptide of the present invention has biological characteristics similar to those of Gas6 full-length proteins, with an effect of enhancing the phagocytic functions of retinal pigment epithelium.
Type:
Grant
Filed:
December 30, 2019
Date of Patent:
June 22, 2021
Assignee:
Beijing Tongren Hospital, Capital Medical University
Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
Type:
Grant
Filed:
July 5, 2016
Date of Patent:
June 22, 2021
Assignee:
AVIXGEN INC.
Inventors:
Young Myeong Kim, Yi Yong Baek, Won Jin Park, Jeong Hun Kim, Dong Hyun Jo
Abstract: Disclosed are polypeptides including at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
Type:
Grant
Filed:
September 29, 2016
Date of Patent:
June 22, 2021
Assignees:
PARIS SCIENCES ET LETTRES—QUARTER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE AL RECHERCHE MÉDICALE)
Inventors:
Guy Tran Van Nhieu, Cesar Valencia-Gallardo, Nicole Quenech'Du
Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.
Type:
Grant
Filed:
April 1, 2020
Date of Patent:
June 15, 2021
Assignee:
ZIH YUAN TANG BIOTECHNOLOGY CO., LTD.
Inventors:
Shoei-Sheng Lee, Ming-Jai Su, Lung-Jr Lin, Chao-Min Hsu
Abstract: Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (IAPP) polypeptides, which are more soluble at neutral pH than the wild-type human islet amyloid polypeptide (hIAPP) protein are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides to be delivered to a subject in a single injection with an insulin agent. Methods and pharmacological compositions for treating an abnormal condition, such as an amyloid-based disease or type-1 diabetes in a subject are also disclosed.
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
June 8, 2021
Assignee:
The Research Foundation for The State University of New York
Inventors:
Daniel Raleigh, Rehana Akter, Andisheh Abedini
Abstract: Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein.
Type:
Grant
Filed:
September 24, 2018
Date of Patent:
June 8, 2021
Assignee:
Whitehead Institute for Biomedical Research
Inventors:
Hidde L. Ploegh, Martin D. Witte, Nicholas C. Yoder
Abstract: Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.
Type:
Grant
Filed:
November 9, 2017
Date of Patent:
June 8, 2021
Assignee:
Baylor College of Medicine
Inventors:
Robert Allen Britton, Catherine Tomaro-Duchesneau
Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Abstract: The effects of hepcidin treatment on mitigating ischemia reperfusion injury (IRI) and acute kidney injury (AKI) by decreasing iron availability and ROS-mediated cell death were tested. Wild type (WT) C57Bl/6 and hepcidin knock out (Hamp?/?) mice were treated with saline or 50 ?g of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-theme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-heme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
June 1, 2021
Assignee:
University of Virginia Patent Foundation
Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
May 25, 2021
Assignee:
MannKind Corporation
Inventors:
Keith A. Oberg, Joseph Sulner, Marshall L. Grant
Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
May 18, 2021
Assignee:
THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.
Type:
Grant
Filed:
March 9, 2020
Date of Patent:
May 4, 2021
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.
Type:
Grant
Filed:
March 9, 2020
Date of Patent:
May 4, 2021
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.
Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.
Abstract: Provided is a novel peptide and a cosmetic composition for inhibiting a skin-aging or a skin-wrinkle formation including the same. The peptide has activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins significantly.
Type:
Grant
Filed:
June 23, 2020
Date of Patent:
April 27, 2021
Assignee:
College of Medicine Pochon CHA University Industry-Academic
Cooperation Foundation
Abstract: This document relates to compositions comprising a non-covalently bound complex comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.
Abstract: Methods for treating retinopathy are provided and include administering an effective amount of a polypeptide antagovist of a Na/K ATPase/Src receptor complex to a subject. The retinopathy can include diabetic retinopathy. Methods of decreasing angiogenesis in a retinal vasculature are also provided and include the step of administering, such as by intravitreous injection, a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof.
Type:
Grant
Filed:
December 30, 2016
Date of Patent:
April 13, 2021
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION